Advertisement
UK markets open in 3 hours 52 minutes

  • NIKKEI 225

    38,329.39
    +777.23 (+2.07%)
     

  • HANG SENG

    17,138.61
    +309.68 (+1.84%)
     

  • CRUDE OIL

    83.37
    +0.01 (+0.01%)
     

  • GOLD FUTURES

    2,335.00
    -7.10 (-0.30%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • Bitcoin GBP

    53,489.95
    -107.72 (-0.20%)
     

  • CMC Crypto 200

    1,433.99
    +19.23 (+1.36%)
     

  • NASDAQ Composite

    15,696.64
    +245.33 (+1.59%)
     

  • UK FTSE All Share

    4,378.75
    +16.15 (+0.37%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

Mylan to Buy Aspen Pharmacare's Thrombosis Business in Europe

Zacks Equity Research
·2-min read

Mylan N.V. MYL announced an agreement to acquire Aspen Pharmacare Holdings Limited's thrombosis business in Europe for €641.9 million.

The portfolio consists of well-established injectable anticoagulants sold in Europe under the brand names — Arixtra, Fraxiparine, Mono-Embolex and Orgaran. These products accounted for combined net sales of approximately €231 million for the 12 months ended Jun 30, 2020.

The transaction is expected to be immediately accretive to Mylan upon closing. Upon closing of the transaction, Mylan expects to fund an upfront payment of €263.2 million to Aspen from existing cash. In addition, Mylan will use the cash generated from operations to make the final deferred payment of €378.7 million on Jun 25, 2021. The closing of the proposed sale is expected to be completed before the year-end.

Aspen will retain manufacturing and product supply responsibilities and supply Mylan with finished products.

The acquisition is also expected to be accretive to Viatris upon the completion of Mylan's previously announced combination with Pfizer’s PFE Upjohn that is expected to close in the fourth quarter of 2020.

ADVERTISEMENT

The acquisition of this thrombosis portfolio will broaden Mylan's European business and make it the second-largest supplier of these products to patients in Europe. It complements and expands Mylan's complex injectables offering and presence in hospitals.

Mylan’s stock has lost 23.9% in the year so far compared with the industry’s decline of 12.6%.

Last month, the company reported second-quarter results, wherein earnings and revenues beat estimates. The coronavirus outbreak and the subsequent lockdown negatively impacted customer buying patterns. However, Wixela Inhub, the generic of GlaxoSmithKline’s GSK Advair Diskus, and Yupelri, developed in collaboration with Theravance Biopharma TBPH, continued to boost growth.

Mylan currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.

The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Mylan N.V. (MYL) : Free Stock Analysis Report
 
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
 
Theravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research